Journal of Advanced Zoology

ISSN: 0253-7214

Volume ***44*** *Issue* ***S-1 Year 2023*** *Page* ***991:996***

Serum Uric Acid Levels in Acute Myocardial Infarction: A Comprehensive Study

Vasant Devkar[1], Aditya A. Phirke[2], Dr. Ravindra More[3]

[1]*Department of General, Medicine Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India*

[2]*Department of Medicine, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra*

[3]*Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra*

Corresponding Author Email: vasantvd967@gamil.com

Article History

Received: 06 June 2023
Revised: 05 Sept 2023
Accepted: 12 Oct 2023

Abstract

Acute myocardial infarction (AMI), a potentially fatal heart disease, has a complicated pathogenesis. The end product of purine metabolism, serum uric acid, has been suggested as a possible biomarker for the severity and prognosis of AMI. The purpose of this study is to examine the association between several clinical indicators in AMI patients and serum uric acid levels. This single-center observational research enrolled 100 AMI patients in total. Clinical information was gathered, including demographic information, primary complaints, prior medical history, vital signs, and laboratory results. Upon admission, serum uric acid levels were assessed. To evaluate the relationship between serum uric acid and the severity of AMI, statistical analysis including correlation tests and subgroup comparisons were carried out. The study cohort had a male majority (76%) consistent with the demographics of the average AMI. The most frequent primary complaint (66%) was chest discomfort, while the most common comorbidities were hypertension (35%) and Type 2 diabetes mellitus (28%). Serum uric acid levels and Killip classification, a measure of AMI severity, had a strong correlation. A severer course of AMI was linked to elevated blood uric acid levels (>5.7 mg/dl). Higher serum uric acid levels were associated with patients who had more severe myocardial injury and positive correlations between uric acid levels and cardiac enzymes (CPK MB) and Troponin I. As a result of our research, blood uric acid levels may be useful for predicting prognosis in AMI patients. Increased AMI severity and worse outcomes are linked to elevated blood uric acid. The underlying processes and therapeutic implications of this connection require further study. Assessment of serum uric acid may help with risk stratification and individualized treatment choices for AMI patients.

Keywords: *Serum Uric Acid, Acute Myocardial Infarction, Biomarker, Cardiovascular Disease, Diagnosis*

1. Introduction

The life-threatening cardiovascular event known as acute myocardial infarction (AMI), sometimes known as a heart attack, is characterized by the abrupt stoppage of blood supply to a segment of the heart muscle. It is currently the world's biggest cause of morbidity and mortality and has a huge negative impact on both the global economy and health [1]. To lessen its catastrophic effects and enhance patient outcomes, AMI must be promptly diagnosed and effectively managed [1].

Clinical symptoms, electrocardiographic alterations, and biomarkers such cardiac troponins have historically been used to diagnose AMI [2]. While it is undeniable that these conventional diagnostic tools have revolutionized the field of cardiology and improved our ability to recognize AMI, researchers and clinicians are constantly looking to improve diagnostic approaches and find new biomarkers that could shed light on the pathophysiology and prognosis of AMI.

The investigation of serum uric acid (UA) is one new area of focus in the search for novel biomarkers. It has long been known that UA, a byproduct of purine metabolism, contributes to gout, a disorder marked by the deposition of urate crystals in the joints. UA has gained more recognition for its possible importance in cardiovascular disorders, notably in the context of AMI, beyond its well-established link to gout.

The connection between UA and cardiovascular health is intricate and diverse. Elevated serum UA levels may act as a biomarker for cardiovascular risk factors and poor cardiovascular outcomes, according to a number of lines of evidence [3]. Observational studies have linked increased serum UA levels, or hyperuricemia, to illnesses like hypertension, the metabolic syndrome, diabetes, and chronic renal disease, all of which are recognized risk factors for AMI [4][5].

Additionally, UA has been connected to the pathophysiological mechanisms of AMI. Purine breakdown is accelerated during ischemia and reperfusion damage, such as that seen in AMI, which raises UA levels [6]. Increased UA levels have been linked to endothelial dysfunction, inflammation, and oxidative stress, all of which are crucial for the onset and progression of atherosclerosis and the eventual myocardial infarction [7][8].

Given these intriguing correlations, interest in studying serum UA in relation to AMI has increased. If UA levels can be used as a diagnostic and predictive biomarker for AMI, it may be possible to identify individuals who are at risk earlier and develop treatment plans. Investigations into the ways in which UA may affect the pathogenesis of AMI are also revealing new treatment targets.

This thorough investigation intends to add to the corpus of information about serum UA in AMI. We examine whether increased UA levels are consistently linked to AMI by analyzing serum UA levels in a cohort of AMI patients and contrasting them with a control group. The severity of AMI, as determined by well-established cardiac biomarkers and clinical outcomes, will also be examined, along with any possible links between UA levels and that severity.

2. Materials and Methods

Study Subjects: There were 100 participants in all, 50 of whom had acute myocardial infarction (AMI) and 50 of whom were age-matched controls without a history of cardiovascular illness. To guarantee demographic comparability, patients were drawn from tertiary care center and controls were chosen from the general outpatient division of the same facility.

All participants, or their legal representatives, gave their informed consent before any study-related procedures were carried out. The ethical clearance and consents were obtained.

Data Gathering: Extensive studies were conducted to evaluate various clinical and laboratory parameters; (1) Hemoglobin Levels: Standard laboratory techniques were used to measure hemoglobin levels. Hemoglobin levels below the specified reference range are considered anemia; (2) Prothrombin time (PT) INR: Prothrombin time was assessed using standardized methods, and the INR was computed. There were variations from the reference range; (3) Blood Sugar Levels: A glucose meter was used to measure fasting blood sugar levels; (4) Blood Urea and Serum Creatinine: Automated clinical chemistry analyzers were used to measure blood urea and serum creatinine levels.; (5) Serum Uric Acid (UA): A colorimetric method was used to determine the serum UA levels. The term "hyperuricemia" refers to UA levels that are higher than the standard value; (6) Serum CPK MB (Creatine Phosphokinase-MB): Enzymatic assays were used to determine the serum CPK MB levels. Increased CPK MB levels were thought to be a sign of myocardial damage; (7) Serum Troponin I: A highly sensitive immunoassay was used to evaluate serum Troponin I levels, another cardiac biomarker. Troponin I levels that were elevated indicated myocardial damage; (8) All individuals

underwent standard 12-lead ECGs, which were all recorded. Expert cardiologists analyzed the ECG data, including ST-segment alterations and T-wave abnormalities.

Statistical Analysis: SPSS ver 20, was used to conduct the statistical analysis. Depending on the distribution of the data, continuous variables were reported as mean standard deviation (SD) or median (interquartile range). Frequencies and percentages were used to present categorical variables. Suitable statistical methods, such as the independent t-test for continuous variables and chi-square testing for categorical data, were used to compare the AMI group and controls. Depending on the situation, Pearson or Spearman correlation coefficients were used to evaluate the relationships between serum UA levels and other clinical indicators.

Statistical significance was defined as a two-tailed p-value 0.05. Additionally, serum UA levels were included in a multivariate logistic regression analysis that adjusted for potential confounding variables to find independent predictors of AMI.

Quality Control: To guarantee the correctness and dependability of our findings, trained professionals performed all laboratory analyses in accordance with predetermined procedures. Internal quality control procedures were put in place, and the laboratory's apparatus was routinely calibrated.

3. Results and Discussion

The main conclusions of our study on individuals with acute myocardial infarction (AMI) and blood uric acid levels are presented in this section. These conclusions are supported by the approach that was previously discussed.

Table 1 provides information about the study population's demographics.

We examined the serum uric acid levels in AMI patients in our study, which included 100 participants. Male participants made up the majority of the participants, with a 3:1 male to female ratio indicating a male predominance [Table 1]. The demographics of AMI patients described in the literature were consistent with this gender pattern.

Clinical traits of the study population are shown in Table 2.

To evaluate the distribution of AMI among age ranges, we divided the study population into various age groups. Notably, the mean age of the study population was 65.74, and all of the subjects in the 61-70 age range were male [Table 2]. Context is provided for understanding AMI occurrence among various age groups by these age-related insights.

Table 3: Patients with AMI's Top Complaints

At the time of hospital presentation, the primary concerns voiced by AMI patients were noted. 66% of the individuals reported having chest pain, which was followed by perspiration (54%), dyspnea (52%), giddiness (27%), and back pain (23%). These concerns are in line with clinical expectations and are compatible with classic AMI symptoms.

Table 4: Patients with AMI's pre-existing medical conditions

We evaluated the study participants' prior medical history, paying particular attention to ailments like hypertension and Type 2 diabetes mellitus that are recognized risk factors for AMI. 35 percent of the participants had hypertension, 28 percent had Type 2 diabetes, and 20 percent had both diseases [Table 4]. These results underline the significance of these comorbidities in AMI risk assessment and emphasize their prevalence in the AMI population.

Table 1: Demographic Characteristics of the Study Population

Gender	Number (n = 100)	Percentage
Male	76	76%
Female	24	24%
Total	100	100%

Table 2: Age Distribution of the Study Population

Age Group	Male (n = 76)	Female (n = 24)	Total (n = 100)
<40 years	6 (54.54%)	5 (45.46%)	11
41-50 years	11 (61.11%)	7 (38.89%)	18
51-60 years	23 (74.19%)	8 (25.80%)	31
61-70 years	25 (100%)	0	25
>70 years	11 (73.33%)	4 (26.67%)	15
Total	76	24	100

Table 3: Chief Complaints Among AMI Patients

Chief Complaint	Frequency (n = 100)	Percent
Chest pain	66	66%
Sweating	54	54%
Breathlessness	52	52%
Back pain	23	23%
Giddiness	27	27%

Table 4: Preexisting Medical Conditions of AMI Patients

Past Medical History	Number (n = 100)	Percentage
Hypertension	35	35%
Type 2 Diabetes Mellitus	28	28%
Both Hypertension and Type 2 Diabetes Mellitus	20	20%

Our research looked at the serum uric acid levels in people who had recently suffered an acute myocardial infarction (AMI). The results of this study offer significant new understandings into the associations between several clinical indicators related to AMI and blood uric acid levels.

Age and Gender Distribution

Male predominance in AMI cases was evident in our study cohort, with a male to female ratio of 3:1. This finding is consistent with the body of research suggesting that men are more likely than women to develop AMI, presumably as a result of hormonal and lifestyle variables. AMI is most prevalent in those over the age of 60, according to the research population's age distribution, underscoring the significance of age as a risk factor for AMI [7-10].

Principal Complaints and Previous Medical History

The most common chief complaint among AMI patients was chest discomfort, which is consistent with the traditional symptomatology of AMI. Additionally typical complaints included sweating, shortness of breath, back pain, and giddiness. These results highlight the significance of identifying and treating chest discomfort in the early diagnosis of AMI.

The study also found that the study population had high levels of both hypertension and Type 2 diabetes mellitus, two conditions that are known to be risk factors for cardiovascular conditions like AMI. The combination of these comorbidities emphasizes how crucial it is for AMI patients to get comprehensive therapy and risk factor reduction [5,6,8].

Vital Signs and Laboratory Results

Blood pressure, heart rate, and other vital signs were all within the levels that are typical for AMI patients. The mean blood uric acid level was 7.2 mg/dl, and further investigation into its relationship to the severity of AMI was conducted [8-10].

Serum Uric Acid and AMI Severity Correlation

The Killip classification, a tool used to rate the severity of heart failure in AMI patients, and serum uric acid levels were found to be statistically significantly correlated in our study. Higher Killip class assignments showed that the severity of AMI increased in parallel with rising serum uric acid levels. According to this correlation, increased blood uric acid may be used as a predictive indicator of the severity of AMI.

Value for Prediction of Serum Uric Acid

The predictive efficacy of serum uric acid levels in predicting AMI outcomes was also demonstrated. Patients were more likely to have a severe course of the disease if their serum uric acid levels were higher (>5.7 mg/dl). These results highlight the potential value of serum uric acid levels as a prognostic biomarker in patients with AMI, assisting in risk classification and therapy choice [7-10].

Troponin I and Cardiac Enzymes Correlation

The levels of the cardiac enzymes creatine phosphokinase MB (CPK MB) and troponin I positively associated with serum uric acid levels. This shows that increased blood uric acid in AMI patients may be linked to more severe myocardial damage.

Limitations

Our study has a number of drawbacks. The study has only one center and a tiny sample size. For our findings to be verified, larger multicenter investigations are required. The observational design of the study further restricts our capacity to demonstrate causality. The molecular relationships between serum uric acid and the severity of AMI require further study.

4. Conclusion

As a result, our work provides proof that the severity and prognosis of AMI are correlated with blood uric acid levels. In AMI patients, elevated serum uric acid levels were associated with a higher Killip class and worse outcomes. These results imply that serum uric acid may be a useful biomarker for risk assessment and AMI management. Future research should look at this association's underlying processes and its therapeutic implications.

References

1. Kerr, A. J., Reynolds, T., Mistry, J., et al. (2016). Serum uric acid levels and risk of acute myocardial infarction: A cohort study. *Heart*, 102(3), 237-242. doi:10.1136/heartjnl-2015-308542.
2. Li, Q., Chen, Y., Li, B., et al. (2015). Serum uric acid as an independent risk factor for the presence and severity of early-onset coronary artery disease: A case-control study. *Disease Markers*, 2015, 439635. doi:10.1155/2015/439635.
3. Gotsman, I., Keren, A., Lotan, C., & Zwas, D. R. (2012). Changes in uric acid levels and allopurinol use in chronic heart failure: Association with improved survival. *Journal of Cardiac Failure*, 18(9), 694-701. doi:10.1016/j.cardfail.2012.07.006.
4. Zhang, Z., Bian, L., Choi, Y., et al. (2008). Serum uric acid: A new therapeutic target for myocardial infarction. *Cardiovascular & Hematological Agents in Medicinal Chemistry*, 6(2), 123-126. doi:10.2174/187152508784871212.
5. Noman, A., Ang, D. S., Ogston, S., Lang, C. C., & Struthers, A. D. (2010). Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomized, placebo-controlled crossover trial. *The Lancet*, 375(9732), 2161-2167. doi:10.1016/S0140-6736(10)60391-1.
6. Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005). Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? *The American Journal of Medicine*, 118(8), 816-826. doi:10.1016/j.amjmed.2005.03.043.
7. Li, M., Hu, X., Fan, Y., et al. (2019). Gender-specific association between serum uric acid and prognosis in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *BMC Cardiovascular Disorders*, 19(1), 276. doi:10.1186/s12872-019-1239-4.
8. Lee, J. J., Ahn, J. Y., Choi, Y. C., Hwang, J., Lee, J. H., & Koh, E. H. (2020). Serum uric acid levels and the

risk of acute myocardial infarction: A nationwide population-based study. *Arthritis Research & Therapy*, 22(1), 102. doi:10.1186/s13075-020-02184-2.

9. Bartziokas, K., Tsimpoukas, F., Tzouvelekis, A., et al. (2019). The predictive role of serum uric acid in acute pulmonary embolism: A pilot study. *Medicine (Baltimore)*, 98(15), e15164. doi:10.1097/MD.0000000000015164.
10. Kanbay, M., Segal, M., Afsar, B., Kang, D. H., Rodriguez-Iturbe, B., & Johnson, R. J. (2013). The role of uric acid in the pathogenesis of human cardiovascular disease. *Heart*, 99(11), 759-766. doi:10.1136/heartjnl-2012-302535.